Artificial single-chain deoxynucleotide having therapeutic effect to human B cell tumour

A deoxynucleotide and artificial synthesis technology, which is applied in the field of preparations for the treatment of human B lymphocyte tumors, can solve the problems of growth inhibition of B lymphocyte tumor cells, etc.

Active Publication Date: 2006-11-22
CHANGCHUN HUAPU BIOTECHNOLOGY CO LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] 2) The growth of B lymph

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Artificial single-chain deoxynucleotide having therapeutic effect to human B cell tumour
  • Artificial single-chain deoxynucleotide having therapeutic effect to human B cell tumour
  • Artificial single-chain deoxynucleotide having therapeutic effect to human B cell tumour

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Embodiment 1, the design of the artificially synthesized single-stranded deoxynucleotide

[0044] The design sequence is as follows:

[0045] 1. The artificially synthesized single-stranded deoxynucleotide (X1=A, T, G; X2=A, T; Y1=A, T; Y2=A, T, C; L, M=A, T, C, G; n is 0-6)

[0046] 5'-ggggTCgTTCgTCgTTgggggg-3' (SEQ ID NO: 1) [121]

[0047] 5'-ggggATAACgTTgCgggggg-3' (SEQ ID NO: 2) [143]

[0048] 5'-ggggTgCAACgTTCAgggggg-3' (SEQ ID NO: 3) [402]

[0049] 5'-ggggTCCTACgTAggAgggggg-3' (SEQ ID NO: 4) [123]

[0050] 5'-ggggTCCATgACgTTCCTgAAgggggg-3' (SEQ ID NO: 5) [603]

[0051] 5'-gggggACgTCgCCgggggggg-3' (SEQ ID NO: 6) [118]

[0052] 5'-ggATCCgTACgCATgggggg-3' (SEQ ID NO: 7) [320]

[0053] 5'-ggggggAATCgATTCgggggg-3' (SEQ ID NO: 8) [154]

[0054] 5'-gggATgCATCgATgCATCgggggg-3' (SEQ ID NO: 9) [464]

[0055] 5'-ggTgCgACgTCgCAgggggg-3' (SEQ ID NO: 10) [471]

[0056] 5'-gggACgTACgTCgggggg-3' (SEQ ID NO: 11) [390]

[0057] 5'-gggggATCgACgTCgATCgggggg-3' (SEQ ID NO: ...

Embodiment 2

[0235] Embodiment 2, the synthesis of single-stranded deoxynucleotide

[0236] The solid-phase phosphoramidite triester method is used to synthesize DNA fragments. This method has the advantages of high efficiency and rapidity, and has been widely used in DNA chemical synthesis.

[0237] DNA chemical synthesis is different from enzymatic DNA synthesis. The enzymatic DNA synthesis process extends from the 5'→3' direction, while DNA chemical synthesis starts from the 3' end. Concrete reaction steps are as follows:

[0238] 1. Deprotection group

[0239] Use trichloroacetic acid to remove the protective group DMT (dimethoxytrityl) of the nucleotide attached to CPG (Controlled Pore Glass) to obtain a free 5'-hydroxyl terminal for the next condensation reaction use.

[0240] 2. Activation

[0241] The phosphoramidite-protected nucleotide monomer is mixed with tetrazolium activator and enters the synthesis column to form the phosphoramidite tetrazolium active intermediate (its 3...

Embodiment 3

[0249] Example 3, Expression of Toll-like receptor 9 in human B lymphocytic leukemia cells

[0250] 1. Preparation of human chronic B lymphocytic leukemia cells

[0251] Peripheral blood mononuclear cells (PBMC) were obtained from the blood of human chronic B lymphocytic leukemia patients by Ficoll-hypaque gradient centrifugation. CD5 was isolated using B lymphocyte isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) + CD19 + CD23 + Human chronic B lymphocytic leukemia cells with a purity of 95%. The specific operation was carried out according to the method provided by Miltenyi Biotec Company. Using the B or T lymphocyte isolation kit (MiltenyiBiotec, Bergisch Gladbach, Germany), the B or T lymphocytes isolated from normal human PBMC, the obtained B lymphocytes (CD19 + ) and the obtained T lymphocytes (CD3 + ) have a purity of more than 95%. The specific operation was carried out according to the method provided by Miltenyi Biotec (Bergisch Gladbach, Germany). ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an artificial single-chained deoxyriboside and B cell tumour treatment technology and method, which is characterized by the following: inducing B cell tumour occur dying; reinforcing B cell tumour cell to express CD40; treating B cell tumour.

Description

technical field [0001] The invention provides a preparation for treating human B lymphocyte tumors, in particular to artificially synthesized single-stranded deoxynucleotides, which can induce apoptosis of human B lymphocyte tumors and enhance the expression of CD40 in human B cell tumor cells , has a therapeutic effect on human B lymphocyte tumors. technical background: [0002] According to the World Health Organization classification system (WHO classification system), human lymphoid malignancies (lymphoid malignancies) are divided into three main types: B-cell neoplasms (B-cell neoplasms), T-lymphocyte / natural killer cell tumors (T-cell / natural killer(NK)-cell neoplasms) and Hodgkin's lymphoma. Human B lymphocyte tumors (B-cell neoplasms) are further divided into two categories: Precursor B-cell neoplasms and peripheral B-cell neoplasms. Precursor B-cell neoplasms include: precursor B-acute lymphoblastic leukemia / lymphoblastic lymphoma (B-ALL, LBL). Peripheral B-cell n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07H21/00A61K31/7088A61P35/00C12N15/117
CPCC12N15/117C12N2310/17C12N2310/313C12N2310/315A61P35/00A61P35/02A61P37/00A61P37/02A61P43/00C07H21/04C12N15/00A61K31/7088C12N15/11
Inventor 王丽颖包木胜于永利
Owner CHANGCHUN HUAPU BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap